Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era

Naokuni Uike, Ilseung Choi, Mariko Tsuda, Shojirou Haji, Kousuke Toyoda, Youko Suehiro, Yasunobu Abe, Toshinobu Hayashi, Hirofumi Sawamoto, Koichiro Kaneko, Mototsugu Shimokawa, Makoto Nakagawa

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

This retrospective study analyzes the results of radioimmunotherapy (RIT) with 90Y-ibritumomab tiuxetan in 94 Japanese patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma at a single institution. All patients had previously been administered with 1–8 (median 1) regimens of rituximab alone or combined with other chemotherapeutic regimens at a mean age of 64 years. The overall response rate was 90 % and the complete response (CR) rate was 69 %. The median overall survival was not reached and progression-free survival (PFS) was 26 months, respectively, for the early phase 50 patients during a median follow-up period of 46.5 months. In this cohort, the PFS rates for the 50 early phase patients who had undergone ≤2 and ≥3 previous regimens, and for those who achieved CR compared with those who did not (partial response, PR; stable disease, SD; progressive disease, PD) were 38 and 11 months, respectively. Multivariate analysis showed that these two factors were statistically significant (p = 0.0011 and p <0.0001, respectively). The overall incidence of grade ≥3 non-hematological toxicity was 9 %. Two patients died of treatment-related deteriorating hepatitis C. A second malignancy developed in two patients at 10.5 and 3.5 months after treatment. We recommend administering90Y-ibritumomab tiuxetan as early in the disease course as possible, and at the latest as a third-line therapy to maximize the benefits of RIT, which should improve the quality of life for patients.

Original languageEnglish
Pages (from-to)386-392
Number of pages7
JournalInternational journal of hematology
Volume100
Issue number4
DOIs
Publication statusPublished - Oct 9 2014

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Factors associated with effects of <sup>90</sup>Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era'. Together they form a unique fingerprint.

  • Cite this